AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10458713
Drug: Aspirin treatment
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin treatment for 6 weeks
Trial: 2218849
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (control of risk factors for stroke including hypertension, diabetes, and hyperlipidemia, and antiplatelet aggregant medication)
Trial: 2218849
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment plus superficial temporal‐to‐middle cerebral artery bypass
Trial: 2218849
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment plus carotid endarterectomy
Trial: 31087723
Drug: Disulfiram treatment
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram treatment for 12 weeks
Trial: 16454830
Drug: Intranasal mupirocin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal mupirocin, arbekacin inhalation, and oral sulfamethoxazole/trimethoprim (Group C)
Trial: 8375242
Drug: Ala 20
RxNorm normalized name: emtricitab/rilpiviri/tenof ala 200 mg-25 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ala 20 g orally
Trial: 8375242
Drug: Ala 40
RxNorm normalized name: Nucala 40 MG in 0.4 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ala 40 g orally
Trial: 8375242
Drug: Terbutaline 2.5
RxNorm normalized name: terbutaline 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 2.5 mg orally
Trial: 8375242
Drug: Terbutaline 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 5.0 mg orally
Trial: 8375242
Drug: Subcutaneous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous terbutaline 0.25 mg
Trial: 8375242
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline 0.4 mg
Trial: 28857147
Drug: Ambrisentan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan (5 mg)
Trial: 20420792
Drug: Prestodol (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prestodol (test formulation)
Trial: 1769635
Drug: Nifedipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (2 x 20 mg retard)
Trial: 1769635
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Clonidine and Nifedipine (C/N)
Trial: 31479003
Drug: Inhaled iloprost
RxNorm normalized name: iloprost Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled iloprost for 5 min
Trial: 28794410
Drug: Advanced oral
RxNorm normalized name: Imodium Advanced Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced oral hygiene care programme (AOHCP) comprising a powered toothbrush, 0.2% chlorhexidine mouthrinse, and oral hygiene instruction
Trial: 28794410
Drug: Advanced oral
RxNorm normalized name: Imodium Advanced Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced oral hygiene care programme (AOHCP)
Trial: 28794410
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral hygiene care programme (COHCP)
Trial: 23126237
Drug: Budesonide/formoterol maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol maintenance and reliever therapy (160/4.5 μg 1 inhalation twice daily plus as-needed budesonide/formoterol 160/4.5 μg)
Trial: 23126237
Drug: Budesonide/formoterol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol plus terbutaline (160/4.5 μg 1 inhalation twice daily plus as-needed terbutaline 0.4 mg)
Trial: 20101851
Drug: Follitropin alpha
RxNorm normalized name: follitropin alpha
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin alpha with 25 IU human chorionic gonadotropin (hCG) daily
Trial: 15605667
Drug: naproxen 500mg
RxNorm normalized name: NAPROXEN 500MG TAB
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen 500mg twice daily
Trial: 8333639
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg IM atropine
Trial: 28869825
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy plus the Memory Support Intervention (CT + Memory Support)
Trial: 28869825
Drug: Cognitive therapy-as-usual
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy-as-usual (CT-as-usual)
Trial: 23626461
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg plus Metformin
Trial: 18266400
Drug: Alendronic acid
RxNorm normalized name: Alendronic Acid
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronic acid 5 mg/day
Trial: 18266400
Drug: Risedronic acid
RxNorm normalized name: Risedronic acid
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Risedronic acid 2.5 mg/day
Trial: 15932834
Drug: Extended regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended regimen of norelgestromin/ethinyl E2 transdermal patch (weekly application for 12 consecutive weeks, 1 patch-free week, and 3 more consecutive weekly applications, n = 158)
Trial: 15932834
Drug: Cyclic regimen
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic regimen (4 consecutive cycles of 3 weekly applications and 1 patch-free week, n = 81)
Trial: 12792297
Drug: E(2)/NETA (0.025/0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E(2)/NETA (0.025/0.125 mg/day)
Trial: 11126377
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion (HAI) therapy
Trial: 11126377
Drug: HAI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI with systemic chemotherapy following hepatic resection
Trial: 8971665
Drug: Moxa-only treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxa-only treatment
Trial: 8971665
Drug: Holistic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holistic treatment style
Trial: 1459154
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg KLH per month for up to 1 year
Trial: 6695853
Drug: Involved field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved field radiotherapy (IF RT) plus six cycles of combination chemotherapy (CT)
Trial: 29550383
Drug: BP1001 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP1001 monotherapy (90 mg/m2)
Trial: 29550383
Drug: BP1001 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP1001 monotherapy
Trial: 29550383
Drug: BP1001 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP1001 plus low-dose cytarabine
Trial: 26836781
Drug: A+M (amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A+M (amoxicillin and metronidazole)
Trial: 24625583
Drug: 4 weeks
RxNorm normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of intramuscular streptomycin
Trial: 24625583
Drug: 8 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of intramuscular streptomycin
Trial: 20214755
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of antiretroviral therapy based on WHO clinical criteria
Trial: 17373743
Drug: Sodium butyrate
RxNorm normalized name: Sodium butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium butyrate coated tablets (1 gram)
Trial: 8562036
Drug: Thymostimulin (TP1)
RxNorm normalized name: thymostimulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin (TP1) 1.0 mg/kg
Trial: 8562036
Drug: Thymostimulin (TP1)
RxNorm normalized name: thymostimulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin (TP1) 2.0 mg/kg
Trial: 8562036
Drug: Thymostimulin (TP1)
RxNorm normalized name: thymostimulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin (TP1) 0.5 mg/kg
Trial: 2653713
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of CTX every 6 hr
Trial: 2653713
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of CTX every 8 hr
Trial: 2653713
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of CTX every 12 hr
Trial: 23835291
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of zoledronic acid (ZA) given 1 week before beginning ADT (arm 1)
Trial: 23835291
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of zoledronic acid (ZA) given 6 months after beginning ADT (arm 2)
Trial: 23835291
Drug: Monthly administration
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly administration of zoledronic acid (ZA) starting 6 months after beginning ADT for a total of 6 doses (arm 3)
Trial: 21812904
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg and 400 mg
Trial: 20139548
Drug: Parenteral opioid/sedative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral opioid/sedative (pentazocine/promethazine)
Trial: 20139548
Drug: Parenteral opioid/sedative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral opioid/sedative
Trial: 12144644
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sodium cromoglycate (SCG) and salbutamol (administered as a nebulized solution)
Trial: 12144644
Drug: Salbutamol (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (administered as a nebulized solution)
Trial: 12144644
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) (administered as a nebulized solution)
Trial: 9502092
Drug: Intra-oral sonography
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-oral sonography
Trial: 2568645
Drug: Metaclazepam 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaclazepam 15 mg per day
Trial: 2568645
Drug: Diazepam 15
RxNorm normalized name: diazepam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 15 mg per day
Trial: 192441
Drug: 5-Fluorouracil (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Fluorouracil (oral or intravenous)
Trial: 31538430
Drug: Short-term exposure
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term exposure to PM10 (exceeding 100 μg/m³)
Trial: 31538430
Drug: Very short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Very short-term exposure to PM10 (exceeding 100 μg/m³ for 2 hours)
Trial: 31538430
Drug: Short-term exposure
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term exposure to PM2.5 (exceeding 50 μg/m³)
Trial: 31538430
Drug: Very short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Very short-term exposure to PM2.5 (exceeding 50 μg/m³ for 2 hours)
Trial: 15333593
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (COC) (19 subjects)
Trial: 9563738
Drug: Zileuton (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton (600 mg, four times daily)
Trial: 8169699
Drug: Cephalothin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalothin (1 g i.v. every 6 h for four doses)
Trial: 30925579
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for painful UBCs
Trial: 30925579
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment for painless UBCs
Trial: 30925579
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment for fractured, nondisplaced and mildly displaced proximal humerus UBCs
Trial: 30925579
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment for mildly displaced pathologic humerus shaft fractures
Trial: 30925579
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment for severely displaced pathologic proximal humerus fractures
Trial: 30925579
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for severely displaced pathologic proximal humerus fractures
Trial: 30925579
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for severely displaced humerus shaft fractures
Trial: 16642224
Drug: Hepatocyte growth
RxNorm normalized name: Dna (human hepatocyte growth factor plasmid pvax1 cdna)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatocyte growth factor (HGF) 80-120 mg daily
Trial: 10881805
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (300-mg bolus and 20 mg x kg(‐1) x day(‐1) for 3 days)
Trial: 10881805
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (150-mg bolus and 10 mg x kg(‐1) x day(‐1) for 3 days)
Trial: 25212080
Drug: MF59‐adjuvanted, trivalent,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59‐adjuvanted, trivalent, influenza vaccine (ATIV)
Trial: 25212080
Drug: Non‐adjuvanted, trivalent,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐adjuvanted, trivalent, influenza vaccine (TIV)
Trial: 18793546
Drug: Epoetin-beta 6,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin-beta 6,000 IU (0.3 ml)
Trial: 18793546
Drug: Darbepoetin-alpha 30
RxNorm normalized name: Darbepoetin
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin-alpha 30 mg (0.3 ml)
Trial: 12150618
Drug: Topical budesonide
RxNorm normalized name: budesonide Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical budesonide (256 microg daily)
Trial: 31566307
Drug: Nintedanib 150
RxNorm normalized name: nintedanib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 150 mg twice daily (UIP-like fibrotic pattern)
Trial: 29089019
Drug: Lotilaner (Credelio™)
RxNorm normalized name: lotilaner Chewable Tablet [Credelio]
DrugBank: Lotilaner (DB17992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotilaner (Credelio™) at a minimum recommended dose rate of 20 mg/kg
Trial: 21368429
Drug: Rabdosia rubescens
RxNorm normalized name: Isodon rubescens top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabdosia rubescens aqueous extract, 220 mL once a day for 30 days
Trial: 21368429
Drug: Placebo, 220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 220 mL once a day for 30 days
Trial: 19142085
Drug: Carbohydrate‐rich drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate‐rich drink (400 ml) at 6‐7 a.m.
Trial: 19142085
Drug: Overnight intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overnight intravenous 5% glucose infusion (1000 ml)
Trial: 15494915
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of coenzyme Q twice daily for 3 months
Trial: 3737440
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acetaminophen 1000 mg and codeine phosphate 60 mg
Trial: 29154277
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg twice a day
Trial: 29154277
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg twice a day (monotherapy)
Trial: 29154277
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg twice a day (add-on therapy)
Trial: 24457999
Drug: beta-alanine (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-alanine (6.4 g/day for 6 weeks)
Trial: 24457999
Drug: placebo (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (6.4 g/day for 6 weeks)
Trial: 23183517
Drug: n‐3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 PUFA (eicosapentaenoic and docosahexaenoic acid ethyl esters, 3.0 g/d)
Trial: 15823787
Drug: Sequential intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential intervention for physical activity followed by fat intake
Trial: 15823787
Drug: Sequential intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential intervention for fat intake followed by physical activity
Trial: 11994339
Drug: DHEA (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (30 mg/d if <45 yr of age and 20 mg if >=45 yr of age) for 6 months
Trial: 7802305
Drug: PCEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA with sufentanil and concomitant infusion of sufentanil
Trial: 7802305
Drug: PCEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA with sufentanil and concomitant infusion of saline (control)
Trial: 380630
Drug: Multiple intradermal
RxNorm normalized name: Skin Test Antigens, Multiple Intradermal Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple intradermal injections of absolute alcohol
Trial: 380630
Drug: Water injections
RxNorm normalized name: WATER FOR INJECTION
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water injections (control)
Trial: 31812227
Drug: IL‐6Rα (interleukin‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐6Rα (interleukin‐6 receptor α chain)
Trial: 31778193
Drug: S. aureus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. aureus vaccine trial (Phase 2)
Trial: 24140184
Drug: Axitinib titration
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib titration (5 mg twice daily during a 4 week lead-in, then titrated to 7 mg and 10 mg if tolerated)
Trial: 24140184
Drug: Non-randomised group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-randomised group (no titration)
Trial: 21902287
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine combined with naltrexone
Trial: 6731771
Drug: Fast-dissolving oral
RxNorm normalized name: melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fast-dissolving oral preparation of oxazepam, administered at least one hour pre-operatively
Trial: 27212429
Drug: bOPV (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bOPV (3 doses)
Trial: 27212429
Drug: tOPV (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tOPV (3 doses)
Trial: 27212429
Drug: bOPV +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bOPV + 1 dose IPV
Trial: 27212429
Drug: bOPV +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bOPV + 2 doses IPV
Trial: 27212429
Drug: IPV (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPV (1 or 2 doses)
Trial: 22304891
Drug: Suffocation script
RxNorm normalized name: Scomber scriptus flesh
DrugBank: Atlantic mackerel (DB15542)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suffocation script condition (CS+) with inhalation of 35% CO(2) as UCS
Trial: 22304891
Drug: Neutral script
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral script condition (CS-) with inhalation of room air
Trial: 22304891
Drug: Urgency script
RxNorm normalized name: Scomber scriptus flesh
DrugBank: Atlantic mackerel (DB15542)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urgency script condition (CS-) with inhalation of room air
Trial: 17606546
Drug: New diaper‐changing,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New diaper‐changing, hand‐washing, and food‐preparation equipment
Trial: 18705977
Drug: High-intensity implementation
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity implementation strategy for intravenous thrombolysis